Prostaglandin A (PGA) exhibits antiviral activity against RNA and DNA viruses. The effect of PGA, on vesicular stomatitis virus (VSV) was investigated. When VSV-infected L-1210 cells were kept in the presence of PGA, the amount of all five viral proteins and their respective mRNAs was dose-dependently decreased. To determine whether the effect was on viral transcription or translation, the temperature-sensitive VSV mutant tsG 41 was employed. This is a good model system for the investigationof primary transcription; at the restrictive temperature of 39 °C, tsG 41 is unable to replicate but can transcribe viral mRNA. Mutant mRNA synthesis was strongly inhibited by PGA, at this temperature, indicating that the major effect is on primary transcription. This conclusion is supported by data demonstrating that in vitro transcription of viral genomic RNA was also inhibited by PGA~.
Introduction
Prostaglandins (PGs) are C20 polyunsaturated fatty acids which are synthesized in eukaryotic cells, mainly from arachidonic acid (Nelson et al., 1982) . These compounds modulate a variety of cellular activities including cell cycle progression (Ohno et al., 1988b) , cellular growth (Santoro et al., 1986; Honda et al., 1987) , aggregation of platelets (Whittle et al., 1978) and many functions of the immune system (Goodwin & Webb, 1980) . PGs of the A series (PGAs) inhibit virus rep!ication in several host-virus systems including vaccinia (Santoro et al., 1983b; Benavente et al., 1984) , influenza (Santoro et al., 1988) , herpes simplex type 2 (Yamamoto et al., 1987) , Sendai (Santoro et al., 1980 (Santoro et al., , 1982 (Santoro et al., , 1987 (Santoro et al., , 1989a , encephalomyocarditis (Ankel et at., 1985) and vesicular stomatitis (VSV) (Santoro et al., 1983a) viruses.
In an attempt to understand the molecular mechanism of the antiviral activity of PGA~ we have studied the effects of this compound on VSV, a ssRNA virus of negative polarity belonging to the Rhabdoviridae. Two early RNA-dependent synthetic events, transcription of viral mRNA, and full-length plus-sense RNA, require the infecting negative-sense RNA strand. The active template is a ribonucleoprotein particle (RNP) which consists of the genomic RNA tightly encapsidated with nucleoprotein N. The RNP particle is also associated with the polymerase complex consisting of the large (L) and non-structural (NS) proteins. In vitro experiments have demonstrated that in addition to the nucleocapsid template only the viral NS and L proteins are necessary for transcription (Emerson & Yu, 1975; Banerjee, 1987) . In the intact virion the RNP is enveloped by the matrix (M) protein and the glycosylated (G) protein embedded in a host-derived lipid membrane. Upon infection, only the nucleocapsid containing L and NS proteins enters into the cytosol of the cell. The RNP-bound polymerase complex immediately starts transcription of mRNAs for translation into their respective viral proteins. Subsequently, full-length plus-sense RNA is synthesized to serve as a template for genomic negative-sense RNA strands which are then used in the bioSynthesis of more viral messages and in the assembly of progeny virus. For an antiviral effect to occur, PGA need not be present during viral adsorption to the cell (Santoro et al., 1980 (Santoro et al., , 1989a Ankel et al., 1985) and so the events following adsorption were studied. The present study describes an investigation of the effects of PGAI on viral transcription and translation in VSV-infected L-1210 cells. It demonstrates for the first time a direct effect of PGs on in vitro transcription.
125I-labelled Protein A was generously supplied by A. Haas, Medical College of Wisconsin. Kits for in vitro translation and nick translation, as well as RNA (0.24 kb to 9.5 kb) and protein (15K to 200K) Mr markers, were purchased from BRL. Cloned cDNAs to N (pN4), NS (pNS319), M (pM309) and G (pG1) mRNA of VSV were generously provided by J. Rose, Yale University, New Haven Conn., U.S.A. Gailione et al., 1981) . cDNA to L mRNA (pSV-VSVL) and antibody against the N terminus of the L protein were a gift from M. Schubert, NIH, Bethesda, Md., U.S.A. (Schubert et al., 1984) . Immobilon-P membranes were purchased from MiUipore and Nytran membranes from Schleicher & SchueU. Insulin, transferrin and methyl cellulose were from Sigma. The RNA extraction kit with caesium trifluoroacetate was supplied by Pharmacia. Staphylococcus aureus suspension was purchased from Calbiochem.
Cells and viruses. L-1210 cells were grown in suspension in RPMI 1640 in the presence of 25 mM-HEPES pH 7-3, 10 mg/l insulin, 5 mgfl transferrin and 4 ixg/l Na2SeO4 to replace serum requirements. L929 cells were grown as a monolayer culture in MEM supplemented with 10% FBS. MDBK cells were grown as monolayers in F-12 medium supplemented with 10% FBS. VSV(I ~ was propagated in L929 cells at an m.o.i, of 0-1. The temperature-sensitive mutant tsG 41 of VSV was a gift from P. Marcus, University of Connecticut, Storrs, Conn., U.S.A. and was also propagated in L929 cells at the permissive temperature of 30 °C.
VSV~I~, used in in vitro transcription assays, was originally a gift from A. Banerjee (Cleveland Clinic Foundation, Cleveland, Ohio, U.S.A.) and was subsequently grown in BHK-21 cells, also from his laboratory. The purification of VSV followed the protocol described by Banerjee et al. (1974) .
Plaque assays and dot-blots. Standard assays consisted of a 1 h infection period with VSV at an m.o.i, of between 10 and 20. Thereafter, unadsorbed virus was removed and PGs added at the indicated concentrations, followed by a 6 h incubation. Virus yields were determined in mini-plaque assays (Langford et al., 1981) . In addition, aliquots of culture supernatant were subjected to serial dilutions with Western blotting buffer in a Minifold I dot-blot apparatus (Schleicher & Schuell) and adsorbed to Immobilon-P membranes by aspiration. The membranes were further treated as in Western blots described below.
SDS-PAGE and Western blots.
Supernatant of cells were concentrated approximately 100-fold in Amicon A25 concentrators to a final volume of 40 ~tl and mixed with an equal volume of 2 x SDS sample buffer (0.5 M-Tris-HCI pH 6.8, 10% glycerol, 10% w/v SDS, 5% 2-mercaptoethanol). Dialysed cell extracts (see below) were mixed with an equal volume of 2 × SDS sample buffer, and 10% SDS-PAGE was done (acrylamide : bisacrylamide, 30:0-8). Proteins were electroblotted onto Immobilon-P in the presence of 10% methanol (Haas & Bright, 1985) . The concentration of anti-VSV~ was optimized and typically used at a 1:10000 dilution. ~25I-labelled Protein A had a specific activity of 2 × 105 c.p.m./ml. Following autoradiography, films were quantified by scanning in a densitometer (Ultrascan; LKB). Autoradiograms of dot-blots treated identically were quantified in an ELISA reader at 550 nm (Bio-Tek).
Preparation of RNA. Samples containing 2 to 4 × 106 L-1210 cells were centrifuged, supernatants were stored separately and pellets were dissolved in 7-6M-guanidinium-HC1 pH 5.0 and 0.1 M-potassium acetate in a final volume of 1-8 ml and then passaged 10 times through a 1 ml insulin syringe (26 gauge). The homogenate was layered over a mixture of 670 ~tl caesium, trifluoroacetate (CsTFA) (density 1.52 g/ml) and 1330 ~1 CsC1 (7.6 M) in SW60 rotor tubes and centrifuged for 24 h at 35000 r.p.m. Thereafter, dissolved proteins in the upper third of the gradient were removed and dialysed against 50 mM-Tris-HCl pH 7.8, containing 150 mM-NaC1, 10 mM-EDTA and 20 mM-2-mercaptoethanol. Then the tubes were inverted, remnants of salt were removed and the visible RNA pellets were redissolved in 30 ~tl TE buffer (10 mMTris-HCl pH 8, 1 mM-EDTA); tubes were rinsed with an additional 30 txl TE. Both RNA-containing solutions were combined and stored at -20 °C.
In vitro translation. Aliquots of total RNA extracts were used to programme an in vitro reticulocyte translation system in the presence of [35S] methionine. Aliquots (5 txl) of undiluted anti-VSV antibody were added and complexes were allowed to form overnight at 4 °C. A second incubation, with the addition of 20 ~tl of S. aureus suspension for 2 h at room temperature, was followed by centrifugation and three washes of the pellet with phosphate-buffered saline (PBS). The final pellets were resolved on 10% SDS gels. After electrophoresis, gels were fixed in 10% TCA, rinsed in H20, soaked in Autofluor (NEN), dried and subjected to fluorography at -80 °C. Fluorograms were quantified densitometrically and bands were expressed as relative peak area.
Northern blot analysis. Equal amounts (5 to 10 ~tg) of RNA in SDS sample buffer were separated on 0.8% TBE-agarose gels, visualized with ethidium bromide and nicked under u.v. light for 5 min. Subsequently, RNA was blotted onto Nytran and baked at 80 °C. Filters were prehybridized for 2 h at 65 °C in 50% formamide, 5 x SSC (150 mM-NaCI, 15 mM-sodium citrate), 1% SDS, 2% Denhardt's solution and 10 ~tg/ml sonicated salmon sperm DNA. This solution was removed and replaced by a fresh aliquot containing one of the five nicktranslated 3zP-labelled probes (see below). Hybridization was allowed to occur for longer than 8 h at 35 °C. After incubation, the filters were washed twice in 2 x SSC and once in 2 x SSC containing 0-1% SDS, for 30 min each at room temperature. Wet filters were wrapped in plastic foil and Konica A medical X-ray film was exposed in the presence of DuPont Lightning Plus intensifying screens at -20 °C or -80 °C.
Nick translation of cDNA probes. Plasmids containing inserts of N, NS, M and G were linearized with PstI and pSV-VSVL was linearized with XhoI. Approximately 10 ~tg of DNA per reaction was nicktranslated according to the manufacturer's protocol using 100 ~tCi [~-32p] dCTP, typically yielding a specific activity of approximately 108 c.p.m.Atg DNA. Unincorporated label was removed in spin columns as described by Maniatis et at. (1982) . Labelled probes were boiled and added directly to the hybridization solution.
In vitro transcription assays. Typically, 2 to 3 ~tl of purified VSV (about 3 mg/ml) was disrupted in 5 ~tl of 1% NP40 at room temperature for 2 min. The reaction mixture (50 ~tl final volume) contained 50 mMTris-HC1 pH 8-0, 5 mM-MgC12, 4 mM-DTT, 0.05 mM-rCTP, 1 mM each of rATP, rGTP, UTP, 20 ~tCi of [~.32p]rCTP (sp. act. > 800 Ci/mmol; NEN) and 20 units RNasin (Promega). Unlabelled nucleotides and 10 x buffer were mixed in a separate tube, then RNasin and labelled rCTP were added. This mixture was combined with disrupted virus, mixed again and transferred to 5 Ixl of 1% NP40 containing PGA1 at various concentrations or other compounds as described in the text. Reaction mixtures were kept at 30 °C on a rocking shaker. Duplicate aliquots of 1 ~tl were taken at the indicated times and spotted on DE81 filter circles. Dried circles were washed five times in 0.5 M-Na2HPO4 for 5 rain each and salt was removed by a rinse with water, followed by washing with 100% ethanol. Filters were dried and counted in a Biosafe II scintillant. controls 7 h after infection with VSV. As shown in Fig. 1 , PGA~ and PGA2 were equally inhibitory to VSV, resulting in 90~ inhibition of progeny virus at 6 and 8 ~tM, respectively. At this concentration, the 9-deoxy PGD2 (equivalent to PGJ2) was somewhat more effective, whereas PGB2, PGE2 and PGF2~ were much less inhibitory. Also, as seen by others, cellular DNA and RNA synthesis was not affected significantly (Santoro et al., 1986) . However, a protein of approximately 70K was induced (data not shown) which had been identified previously as a heat shock protein (Ohno et al., 1988a; Santoro et al., 1989b) . 
Results

Specificity of the antiviral effect
Correlation between viral yield reduction and synthesis of viral proteins
Plaque assays measure the number of infectious particles only and do not answer the question of whether PGAI might cause the production of defective interfering viral particles devoid of infectivity. Therefore, viral protein yield was measured using a dot-blot assay employing a polyclonal anti-VSV antibody which recognizes total viral antigen. Aliquots of samples previously tested in plaque assays were quantified by immunoblotting. Fig. 2 shows the dose-dependent reduction of viral proteins. Increasing concentrations of PGA1 resulted in diminished amounts of VSV antigen in dot-blots of supernatants. As seen in Fig. 3 , the inhibition of infectious virions in the presence of 10 ~tM-PGA~, as measured by plaque assay (Fig. 3 a) , paralleled the release of antibodyspecific viral antigen from cells ( Fig. 3b) in the same experiment. Thus, the overall production of virus particles was inhibited rather than just their infectivity.
In related experiments, VSV-infected L-1210 cells were labelled with [3SS]methionine in the presence and absence of 10~tM-PGAa and radioactive virus was immunoprecipitated. Viral yields in supernatants were tested in plaque assays. The results reveal the same ratio of radioactivity to infectious virions regardless of whether determinations were done on control or PGA~-treated cells (see Table 2 ). Thus, progeny virions released from PGA~-treated cells, although greatly reduced in number, are equally as infectious as those released from untreated cells. , : , • . W , , "r "I" Western blot analysis of VSV proteins from cell extracts kept in the absence or presence of l0 IxM-PGA1. Cells were derived from the experiment described in (a). They were dissolved in guanidinium-HCl and subjected to gradient centrifugation in CsC1/CsTFA. The protein fraction in the upper third of the gradient was dialysed and separated by SDS-PAGE, followed by immunoblotting. 1*C-Labelled Mr markers are on the left and 14C-labelled authentic viral proteins are on the right side of the autoradiograms. In both (a) and (b) lanes 2 to 6 contain material not treated with PGA1, lanes 8 to 12 contain material treated with 10 ~tM-PGA1. Lanes 2 and 8, 3 and 9, 4 and 10, 5 and 11 and 6 and 12 were incubated for 3 h, 6h, 9h, 12h and 20h, respectively. Lanes 1 and 7 are uninfected cells as a control.
( Fig. 4a) . In extracts of PGAl-treated infected cells (Fig.  4b) , the amount of viral proteins never exceeded 6~ of that of untreated controls over the entire time period observed, as determined by scanning of exposed films. These data support the conclusion that PGAl-treated infected cells are able to synthesize all five viral proteins, albeit in reduced amounts, and that the decrease of infectious virions released from cells upon PGA1 treatment is not the result of a preferential block of individual viral proteins. Also, no accumulation of viral proteins occurred within the cells ruling out the possibility of impaired release of progeny virus from cells.
Translation of viral mRNA from PGAl-treated cells
In further experiments, then question of whether PGA had any direct effect on translation under in vitro conditions was investigated• Using a rabbit reticulocyte lysate system, there was no inhibitory effect on translation of mRNAs from VSV or brome mosaic virus in the presence of 10 gM-PGA~, the latter being used as an independent control (data not shown). This suggested that the antiviral activity possibly occurred at an earlier stage of the viral replication cycle, prior to translation. Consequently, the question of whether the inhibitory effect of PGA~ on VSV protein synthesis could be due to non-functional viral mRNA was examined. In vitro translation reactions of VSV mRNA from control and PGAl-treated infected cells were performed to investigate the ability of viral message to be translated. RNA from untreated cells directed the synthesis of increasing amounts of VSV proteins with time. Translation in vitro of RNA aliquots from PGAa-treated cells resulted in roughly half as much protein as that of RNA from untreated cells (data not shown). However, the ratio of the individual proteins did not change much, ruling out the possibility that PGA 1 specifically inhibits synthesis of one viral protein.
The effect of PGA1 on viral mRNA synthesis
The findings above led to the question of whether individual VSV mRNAs were decreased as a consequence of PGAI treatment. Their abundance was determined by Northern blot analysis of agarose gelseparated RNA samples after blotting to nylon membranes. 32p-labelled nick-translated plasmids containing cDNA of the respective viral messages were employed for hybridizations. Fig. 5 shows autoradiograms of and li and 6 and 12, 3 h, 6 h, 9 h, 12 h and 20 h, respectively), was isolated as described before. Aliquots based on total RNA were separated on agarose gels and then transferred onto Nytran membranes which were probed with 32p-labelled nick-translated cDNAs of the respective mRNAs. Equal loading of gels was confirmed by ethidium bromide staining of the gel prior to the transfer (a). a2p-Labelled Northern blots of all five viral mRNAs from infected cells kept in the absence or presence of PGA~ and isolated at the indicated time p.i. In untreated cells, RNA levels increased uniformly until 9 to 12 h p.i. and decreased afterwards, probably due to loss of RNA from disintegrated cells. PGA~-treated cells, on the other hand, synthesized viral RNA at a much lower rate, but also reached peak levels between 9 and 12 h p.i. The same profile was obtained for all viral messages, which excludes the possibility that an altered ratio of viral RNA synthesis is responsible for the antiviral effect. On the contrary, the data argue strongly for PGA~-dependent inhibition of all mRNAs because their levels in treated cells never approached the levels detected in untreated infected cells. Clearly, the amounts of all mRNAs were decreased in the presence of PGA1. The fact that the mobilities of viral RNAs from PGA1-treated cells remained unchanged suggests neither that incomplete mRNAs are synthesized nor that degradation could account for the lower levels of mRNAs present.
HindlII-digested
Effects of PGA 1 on primary transcription
In order to investigate any direct effect of PGA1 on VSV transcription it was necessary to discriminate among primary transcription, replication and secondary transcription. Typically, investigators examined VSV primary transcription by use of an appropriate VSV mutant strain (Marcus & Sekellick, 1978; Masters & Samuel, 1983b) or by examining wild-type VSV transcription in the presence of protein synthesis inhibitors. To distinguish between all these steps the VSV mutant tsG 41 was employed (Pringle, 1970) . Owing to a heat-labile N protein, this mutant cannot replicate at the restrictive temperature of 39 °C but does carry out primary transcription. As a result viral titres decrease three-to fourfold as secondary transcription does not occur (Pringle, 1970) . However, primary transcription of the infecting negative-sense RNA template yields viral mRNAs which are translated into viral proteins. In order to determine whether PGA~ can inhibit primary transcription of tsG 41, the synthesis of viral mRNA in cells infected with the mutant was investigated. Cells were infected at 30 °C for 1 h, then different concentrations of PGA1 were added and the temperature was raised to 39°C. After 6h at the restrictive temperature, cells were harvested, viral yield was determined and RNA was isolated and examined by Northern blot analysis. It should be noted that at the non-permissive temperature no amplification of viral mRNA occurs, which made longer exposure times of probed membranes necessary, resulting in a high background. As a control, plaque assays of sample supernatants at both 30 °C and 39 °C were performed to ensure that results in Northern blots were not due to leakiness of the mutant (data not shown). Fig. 6 shows autoradiograms of all five probed viral mRNAs. A dosedependent decrease of mRNA with increasing concentrations of PGA~ can be observed. The dose-dependent inhibition of tsG 41 mRNA synthesis by PGA~ under conditions that do not allow for any other transcriptional activity strongly supports the conclusion that primary transcription, the first event of RNA synthesis in the viral replication cycle, is the step where PGA~ exerts its major antiviral activity. Indeed, it establishes the fact that the reduction of viral mRNA synthesis by PGA~ is the cause of insufficient protein synthesis, which in turn blocks viral replication, which is dependent on the translation of new proteins. Thus, it can be concluded that the major antiviral activity of PGA1 is the result of inhibition of primary transcription and that inhibition of all subsequent events is a consequence of this effect.
In vitro transcription of VSV
Since primary transcription seems to be the earliest target for PGA1 inhibition of VSV replication, in vitro transcriptions, as described by De & Banerjee (1984) , were performed in an attempt to demonstrate a direct effect of PGA1 on transcription. Purified wild-type VSV particles disrupted by NP40 were incubated with [3:p]rCTP and the three other unlabelled nucleoside triphosphates in the absence or the presence of increasing concentrations of PGA1. As shown in Fig. 7 , PGA1 reduced the rate of transcription in a dose-dependent manner. To achieve 50% inhibition, approximately 500 I~M-PGAx was necessary. The reaction was linear over a period of 1 h. Similar experiments were carried out in the presence of PGE~ and PGE2, whose in vivo effects on VSV are minimal. No inhibition of transcription was observable in these experiments. These data strongly suggest that PGAx can cause direct and specific 
Discussion
It has been observed previously that PGAs and related prostanoids inhibit several DNA and RNA viruses in cell culture and also in infected animals, suggesting that these and similar analogues might be antiviral agents useful in the therapy of viral disease. In the system described here it was demonstrated that VSV yield was inhibited in the presence of prostaglandins A1, A2, 9-deoxy-D2 and to a far lesser extent by B2, E2 and F2. The examination of viral proteins revealed that all five were reduced as a result of PGA1 treatment, indicating that the total number of virions released per cell had decreased. Furthermore, Northern blot analysis showed that these lower amounts of protein were a result of decreased amounts of viral mRNA. By the use of the replication-negative VSV mutant tsG 41, it could be demonstrated that primary transcription, the first synthetic event after viral entry into the cytoplasm, was affected, leading to a dose-dependent reduction of viral message. This mutant offers an alternative to examining wild-type VSV transcription in vivo in the presence of cycloheximide (Masters & Samuel, 1983b) , which has several drawbacks. Firstly, VSV has an absolute requirement for protein synthesis and, because cycloheximide inhibits the synthesis of viral polymerase (NS and L proteins), probing for transcription products, with the exception of those synthesized by the parental enzyme, would be prevented. Secondly, cycloheximide causes, for unknown reasens, an enhancement of VSV mRNA synthesis (Marcus & SekeUick, 1978) . In plaque assays, as well as in dot-blot assays, tsG 41 at the permissive temperature of 30 °C responded dose-dependently to PGA1 treatment with a decrease in virus and protein titres; however, only small amounts of virus were detectable at the restrictive temperature. Plaque assays at two temperatures were performed to monitor leakiness of the mutant and the frequency of revertants but tsG 41 was investigated at the restrictive temperature to avoid virus replication and secondary transcription.
Inhibition of mRNA synthesis was confirmed by in vitro transcription assays where a direct correlation between PGA1 concentration and inhibition of transcription rate could be demonstrated. This work supports the conclusion that the major antiviral effect of PGA1 on VSV replication occurs at the level of primary transcription. In addition, inhibition of replication may subsequently occur because both reactions are catalysed by the same enzyme complex.
Concentrations necessary to diminish transcription in vitro differ markedly from in vivo conditions (6 to 8 ~tM-PGAI to reduce viral yield by 90~). The reasons are yet to be determined but may result from differences in the transcription event intracellularly as compared to in vitro conditions, and might be a reflection of the artificial conditions of the in vitro assay. Another interpretation considers the actual concentrations of PGs within the cells. In the L-1210 cells employed in this study, exogenously supplied inhibitory concentrations of PGA~ were in the range of 10 ~tM compared to the 0.5 to 1 mM concentrations that resulted in inhibition of transcription in vitro. Narumiya & Fukushima (1986) showed that labelled PGA 1 accumulated within L-1210 cells. Due to a carrier system that selectively concentrates certain PGs within the cells, they found a significant increase of label concentration, corresponding to approximately 200 ~tM. Similar observations were described by Bito (1972) , who found a greater than 200-fold tissue-to-medium gradient for certain PGs, which led to considerable intracellular accumulation of PGs. These levels are within the concentration range found to be inhibitory in vitro.
Translation of viral mRNA on the other hand seemed unaffected by PGAa. Neither did the presence of PGA~ change translation in vitro or the ability of VSV mRNA to direct protein synthesis upon treatment of cells. However, protein quantities were diminished by about 50~. This observation is not a true reflection of the 90~ inhibition seen in vivo. A similar discrepancy between in vivo and in vitro translation was described by Masters & Samuel (1983b) , when they translated VSV mRNA from interferon-treated, and untreated cells in vitro. They explained this phenomenon in part with the observation by Rosen et al. (1982) The molecular mechanism underlying the antiviral effect is presently unknown. Fukushima et al. (1982) first discussed the requirement of a reactive ~,/~-unsaturated carbonyl in PGAs for inhibition of tumour growth, an idea also discussed by others (Fukushima & Kato, 1984; Narumiya & Fukushima, 1985; Honn & Marnett, 1985) ; a similar requirement was also suggested for the antiviral activity by Santoro et al. (1987) . Support comes from the observation that there is low antiviral activity of PGEs in vitro, which correlates with a lack of inhibitory activity in the in vitro transcription assay of VSV. A relationship between the antiviral actions of interferons and prostaglandins has been suggested because PGA treatment of murine L cells appeared to augment dsRNA-dependent protein kinase and 2'5'-oligoadenylate synthetase, two enzymes that are induced in interferon-treated cells and believed to be primarily responsible for interferoninduced inhibition of viral replication (Santoro et al., 1983b) . However, in subsequent work no evidence for increased levels of both proteins in PGA-treated L cells was found, suggesting that an interferon-related mechanism for the antiviral effect might be questionable (Ankel et al., 1985) . It was also established that the antiviral effect on encephalomyocarditis virus was unaffected in the presence of actinomycin D under conditions where cellular RNA synthesis is blocked. This indicates that at least for this RNA virus, inhibition of replication must be independent of the induction of cellular proteins (Ankel et al., 1985) . Similar results have now been obtained with VSV, a virus that rapidly and effectively shuts off cellular RNA synthesis. Thus, involvement of induced cellular proteins in the antiviral effect of PGA1 seems unlikely.
Treatment of VSV(orsay)-infected cells with PGA or of Sendai virus-infected cells with PGJ followed by SDS-PAGE separation of viral proteins indicated changes in the mobility of the VSV G protein and the Sendai virus HN protein consistent with deficient glycosylation (Santoro et al., 1983a (Santoro et al., , 1987 . Although there seems to be some increase in the relative proportion of a faster moving protein G band in PGAl-treated samples (Fig.  4a) , it appears to be much less dramatic than the overall decrease of G protein, glycosylated as well as unglycosylated. Thus, although a change of post-translational glycosylation in the presence of PGA~ might occur, this effect seems secondary to the general decrease of all VSV proteins.
Vaccinia virus and herpes simplex virus are DNA viruses of great complexity. Nevertheless, despite fundamental differences in their life cycles to those of RNA viruses, their replication is inhibited by PGAs. Work on these indicated that PGAs inhibit a process that happens after viral adsorption, as, in both cases, antiviral activity was seen when the inhibitor was added post-infection. Based on observations of DNA, RNA and protein synthesis in vaccinia virus-infected cells treated with PGA, it was concluded that the antiviral effect is mediated at the level of transcription and/or translation of viral mRNA (Santoro et al., 1983b; Benavente et aL, 1984) . In studies of herpes simplex virus mRNA in infected cells treated with PGAs, it was shown that synthesis of immediate early protein-specific mRNA was inhibited (Yamamoto et aL, 1987) . The present work supports the conclusion that the major antiviral effect of PGA1 on VSV is on primary transcription and that both synthesis of viral proteins and release of infectious virus are decreased due to this inhibition. Although the precise mechanism by which PGA~ exerts its effect is still unresolved, it is obvious that PGAs are antiviral agents in their own right and their action is unrelated to interferon. Their antiviral activity affects both DNA and RNA viruses but their effect on the latter seems to be of greater importance because at one step in their replication cycle RNA viruses need to transcribe their RNA. The machinery necessary for this step is supplied by the virus because most eukaryotic cells carry no RNA-dependent polymerase. Clearly, if PGAs are able specifically to inhibit this class of enzymes, an important new source for antiviral agents is at hand because a large variety of prostanoids analogous to PGA are available from natural sources or can be synthesized chemically.
